Jan Ouwerkerk

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

Nielka P. van Erp, Hans Gelderblom, Mats O. Karlsson et al. · Clinical Cancer Research · 2007 · 121 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8

Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors

Neeltje Steeghs, Ferry A.L.M. Eskens, Hans Gelderblom et al. · Journal of Clinical Oncology · 2009 · 105 citations

Medicine, Oncology, Pharmacology +15

Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors

Ferry A.L.M. Eskens, Neeltje Steeghs, Jaap Verweij et al. · Journal of Clinical Oncology · 2009 · 45 citations · Full text

Medicine, Oncology, Pharmacology +14

Safe handling of antineoplastic drugs

Rose M. B. Nieweg, Maureen de Boer, Ria C. Dubbleman et al. · Cancer Nursing · 1994 · 34 citations

Health Professions, Oncology, Oncology Nursing +13

Determination of N7-methylguanine in DNA of white blood cells from cancer patients treated with dacarbazine¹

Joost H.M. van Delft, Angela M.C. van den Ende, H.J. Keizer et al. · Carcinogenesis · 1992 · 25 citations

Medicine, Oncology, Pharmacology +9